- |||||||||| Torisel (temsirolimus) / Pfizer
Trial primary completion date: Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer (clinicaltrials.gov) - Mar 16, 2020 P3, N=253, Active, not recruiting, These observations indicate that the ALDH1A3-mTOR axis could be a novel therapeutic target to eradicate drug-tolerant gastric cancer cells. Trial primary completion date: Mar 2020 --> Jun 2020
- |||||||||| Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Clinical, Journal: Current and emerging first-line systemic therapies in metastatic clear-cell renal cell carcinoma. (Pubmed Central) - Mar 8, 2020 Nivolumab/ipilimumab (dual checkpoint inhibitors) seem to be the preferred first-line therapy in poor-risk patients, although cabozantinib, temsirolimus, sunitinib and pazopanib are also recommended...These emerging therapies include the combinations of pembrolizumab/lenvatinib, pembrolizumab/axitinib, avelumab/axitinib and atezolizumab/ bevacizu-mab and seem to introduce the mccRCC therapy in a new auspicious era. Moreover, emerging new targeted therapies and other, beyond ICIs, immunotherapies are currently underway.
- |||||||||| Torisel (temsirolimus) / Pfizer
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: Temsirolimus Adventitial Delivery to Improve Angiographic Outcomes Below the Knee (TANGO) (clinicaltrials.gov) - Feb 19, 2020 P2, N=100, Active, not recruiting, Temsirolimus was well-tolerated with manageable adverse events. Recruiting --> Active, not recruiting | N=60 --> 100 | Trial completion date: Feb 2020 --> Sep 2021 | Trial primary completion date: Aug 2019 --> Sep 2020
- |||||||||| Torisel (temsirolimus) / Pfizer, Sutent (sunitinib) / Pfizer
Journal: Local and distant recurrence of the chromophobe renal cell carcinoma. (Pubmed Central) - Feb 14, 2020 The other three cases were unresectable surgicallyand received sunitinib. One patient now has a stable diseaseand the two others died. Chromophobe renal cell carcinomashowed a greater tendency to metastasize, so requires asurveillance protocol based on the risk of recurrence.
- |||||||||| Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer (clinicaltrials.gov) - Jan 31, 2020 P1, N=278, Active, not recruiting, Not yet recruiting --> Recruiting Trial completion date: Aug 2019 --> Dec 2021 | Trial primary completion date: Aug 2019 --> Dec 2021
- |||||||||| Torisel (temsirolimus) / Pfizer, Zelboraf (vemurafenib) / Roche
Enrollment change, Trial primary completion date, Combination therapy, Metastases: Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer (clinicaltrials.gov) - Jan 23, 2020 P1, N=27, Active, not recruiting, 1 case exhibited a TMB burden of 9 mutations/Mb, indicating it may responde to immune therapy. N=114 --> 27 | Trial primary completion date: Dec 2019 --> Dec 2020
- |||||||||| Torisel (temsirolimus) / Pfizer
Trial completion date, Trial primary completion date, Metastases: Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors (clinicaltrials.gov) - Jan 9, 2020 P1, N=36, Recruiting, Trial completion date: Dec 2019 --> Jul 2020 Trial completion date: Oct 2019 --> Oct 2021 | Trial primary completion date: Oct 2019 --> Oct 2021
- |||||||||| Torisel (temsirolimus) / Pfizer
Journal: Identification and characterization of two novel oncogenic mTOR mutations. (Pubmed Central) - Dec 20, 2019 We also demonstrated that transfection with the novel mutants conferred cells high sensitivities to the mTOR inhibitor temsirolimus. We speculate that human cancers harboring these mTOR mutations, such as ATC and melanoma, may be effectively treated with inhibitors targeting mTOR.
- |||||||||| Journal: Autophagy as a molecular target for cancer treatment. (Pubmed Central) - Dec 20, 2019
In this sense, we also review the shared regulatory pathways that play a role in autophagy and malignant transformation. Finally, anti-cancer therapeutic agents used as either inhibitors or inducers of autophagy have been discussed.
- |||||||||| Koselugo (selumetinib) / Merck (MSD), AstraZeneca
Trial completion date, Combination therapy, Metastases: A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) (clinicaltrials.gov) - Dec 13, 2019 P1, N=140, Active, not recruiting, Finally, anti-cancer therapeutic agents used as either inhibitors or inducers of autophagy have been discussed. Trial completion date: Dec 2019 --> Dec 2020
- |||||||||| Torisel (temsirolimus) / Pfizer, Sutent (sunitinib) / Pfizer
Trial completion date, Trial primary completion date, Metastases: Phase II Study of Alternating Sunitinib and Temsirolimus (clinicaltrials.gov) - Dec 10, 2019 P2, N=37, Active, not recruiting, Trial completion date: Dec 2019 --> Dec 2020 Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2019 --> Dec 2020
- |||||||||| Avastin (bevacizumab) / Roche
Clinical, Journal, Adverse events, HEOR, Real-world evidence: Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database. (Pubmed Central) - Nov 22, 2019 In the US, 1 L TK/VEGF inhibitor uptake in recent years appears largely in line with national approvals and guidelines, with varied 2 L agent use. Although retrospective evaluation of claims data cannot assess underlying causality, insights from these real-world RCC treatment and AE patterns will be useful in informing medical and payer decisions.
- |||||||||| Avastin (bevacizumab) / Roche, everolimus / Generic mfg.
Journal, HEOR: Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer. (Pubmed Central) - Nov 19, 2019 Metaplastic breast cancers (MpBCs) represent <1% of all breast cancers, demonstrate mesenchymal differentiation, and are typically resistant to chemotherapy. Patients with advanced MpBC treated with an mTOR-based systemic therapy regimen had better long-term outcomes compared with patients with nonmetaplastic triple-negative breast cancer treated with the same regimen, suggesting that metaplastic histology may predict benefit from agents targeting the PI3K/Akt/mTOR pathway.
- |||||||||| Combination of Venetoclax and Ibrutinib Increases bcl2-Dependent Apoptotic Priming, Reduces ITK-Phosphorylation and Is Clinically Promising in Relapsed/Refractory T-Prolymphocytic Leukemia (Hall B, Level 2 (Orange County Convention Center)) - Nov 7, 2019 - Abstract #ASH2019ASH_5697;
Results Pairwise combinations screen of venetoclax with candidate small molecule inhibitors and chemotherapeutic drugs on primary T-PLL cells revealed synergistic action of venetoclax with ibrutinib, idelalisib, and 5-azacytidine, and to lower extents Olaparib, Temsirolimus, Ruxolitinib and Belinostat whereas cisplatin antagonized the effect of venetoclax across all patient samples tested (Fig 1b)...Two patients suffering from r/r T-PLL after failing at least two treatment lines including alemtuzumab were treated with the combination of venetoclax and ibrutinib resulting in significant clinical responses with substantial drops in leukocytosis and LDH as well as substantial clinical improvement (Fig 2a, b)...Mechanistically, ibrutinib dephosphorylated ITK in T-PLL cells and, furthermore, enhanced BCL2 dependency, both, in-vivo and in-vitro. Patients treated with the combination venetoclax and ibrutinib experienced profound clinical responses which needs further evaluation in an prospective clinical study on a larger cohort of r/r T-PLL patients.
- |||||||||| everolimus / Generic mfg.
Clinical, Journal: Stomatitis associated with mammalian target of rapamycin inhibition: A review of pathogenesis, prevention, treatment, and clinical implications for oral practice in metastatic breast cancer. (Pubmed Central) - Oct 31, 2019 These results are concordant with our previous findings on ibrutinib and remain persistent. Oral health care providers are on the frontline of oral health care for patients with metastatic breast cancer and are uniquely positioned to provide patient education, advocate accurate reporting of mIAS, and support early identification, monitoring, and prompt intervention to mitigate the severity and duration of this manageable, potentially dose-limiting AE.
|